监督学校治疗在儿童控制不良喘中的作用
Muppala Raju1, Malvika Sagar2, Andrew Bush3
1Department of Pediatrics, Baylor Research Institute, Temple, Texas.
概括
在学校使用吸入性皮质类固醇 (ICS) 改善了儿童的喘控制. 这种干预措施减少了住院住院和增强肺功能,为儿童喘管理提供了有前途的策略.
科学领域:
- 儿科肺病学 儿科肺病学
- 喘管理 喘管理
- 呼吸系统健康 呼吸系统健康
背景情况:
- 吸入性皮质类固醇 (ICS) 治疗的不坚持是儿科喘管理的一个重大挑战.
- 缺乏坚持导致疾病控制不足,并增加了儿童并发症的风险.
研究的目的:
- 评估在学校开始每天一次的ICS给药对控制不良的喘儿童的临床益处.
- 评估基于学校的ICS治疗对关键喘控制指标的影响.
主要方法:
- 对患有控制不良喘的儿科患者进行了回顾性研究,每天处方ICS.
- 数据收集包括皮质类固醇疗程,急诊室访问,住院,症状史和干预前后的肺功能测试.
主要成果:
- 干预后住院病人的数量显著下降 (1.23至0.57,P=0.04).
- 在1秒内强制呼气量 (FEV1) 显著增加 (1.69对1.4L/秒,P=0.02).
- 系统性无类固醇日数增加 (96至141天,P=0.03),表明口服皮质类固醇的需要减少.
结论:
- 基于学校的ICS管理是改善儿童喘控制的可行策略.
- 这种方法可能会导致儿童喘患者的住院减少和增强肺功能.
相关概念视频
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma-IV: Nursing Management
3.2K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.2K
Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317
Asthma: Pathogenesis and Management
461
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
461


